NCT06158490View on ClinicalTrials.gov

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

February 10, 2026

Study Completion Date

October 10, 2026

Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
DRUG

JYP0061 15 mg

Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.

DRUG

JYP0061 30 mg

articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.

DRUG

Placebo

Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.

Trial Locations (1)

Unknown

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY